To appraise the clinical and cost-effectiveness of encorafenib with binimetinib and cetuximab within their marketing authorisation for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
 
Status In progress
Process STA 2018
ID number 1598

Provisional Schedule

Committee meeting: 1 13 August 2020
Expected publication 21 October 2020

Project Team

Project lead Jeremy Powell

Email enquiries

Evidence Review Group / Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick

Timeline

Key events during the development of the guidance:

Date Update
03 December 2019 Invitation to participate
30 September 2019 Please note that following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early -December 2019. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust evidence submission.
02 July 2019 - 30 July 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
21 June 2019 Please note that following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early -December 2019. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust evidence submission.
09 May 2019 In progress, Referred 08 January 2019

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance